论文部分内容阅读
目的 通过改良粪便DNA提取方法 ,探讨粪便K ras突变检测在胰腺癌筛选中的意义。方法 病例来自我院 1994～ 2 0 0 0年住院和门诊患者共 12 7例 ,正常对照 6 0例。通过改良酚 氯仿抽提法提取粪便DNA。通过PCR RFLP方法 ,检测K ras基因第一外显子 12密码子的突变。结果 粪便K ras的扩增成功率为 89.8% (16 8/ 187例 )。胰腺癌患者粪便K ras突变率为 88.0 % (6 6 / 75例 ) ,胰腺良性疾病 (包括腺瘤、慢性胰腺炎和内分泌瘤 )为 5 1.1% (2 4/ 47例 ) ,正常对照组为 19.6 % (9/ 46例 )。结论 通过改良粪便DNA提取方法 ,可明显提高PCR扩增成功率。粪便K ras突变检测可用于胰腺癌的筛选。
Objective To explore the significance of fecal K ras mutation detection in the screening of pancreatic cancer by improving the method of fecal DNA extraction. Methods The cases came from our hospital from 1994 to 2000. There were 127 patients inpatients and outpatients. There were 60 normal controls. Fecal DNA was extracted by modified phenol chloroform extraction. The first exon 12 codon mutation of Kras gene was detected by PCR RFLP. Results The success rate of fecal K ras amplification was 89.8% (16 8/187 cases). The K ras mutation rate was 88.0 % (6 6/75) in pancreatic cancer patients, and benign disease (including adenomas, chronic pancreatitis, and endocrine tumors) was 5 1.1% (24/47) in the pancreatic cancer patients. 19.6% (9/46 cases). Conclusion By improving the fecal DNA extraction method, the success rate of PCR amplification can be significantly improved. Fecal Kras mutation detection can be used for the screening of pancreatic cancer.